Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-05-31
1998-09-15
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241301, 4241371, A61K 39395, C07K 1646
Patent
active
058075488
ABSTRACT:
A humanized chimera antibody, a process for its production and methods for its use are disclosed. The chimera antibody is produced without changing any amino acids of its mouse antibody variable region.
REFERENCES:
Dillman, R.O. et al, J. Clin. Oncol., 2, 881, 1984, "Therapy of Chronic Lymphocytic Leukemia and Cutaneous T-Cell Lymphoma With T101 Monoclonal Antibody".
LoBuglio, A.F., et al, J. Nat. Cancer Institute, 80, 932,1988 "Phase I Trial of Muliple Large Doses of Murine Monoclonal Antibody C017-1A".
Khazaeli, M.B., et al, J. Nat. Cancer Institute, 80, 937, 1988 "Phase I Trial of Multiple Large Doses of Murine Monoclonal Antibody C017-1A".
Courtenay-Luck, N.S., et al, Cancer Res., 46, 6489, 1986 "Development of Primary and Secondary Immune Responses to Mouse Monoclonal Antibodies Used in the Diagnosis and Therapy of Malignant Neoplasms".
LoBuglio, A.F., et al, Proc. Natl. Acad. Sci. USA., 4220, 1989 "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response".
Mueller, B.M., et al, J. Immunol., 144, 1382, 1990 "Enhancement of Anibody-Dependent Cytotoxicity with a Chimeric Anti-GD2 Antibody".
Pukel, C.S., et al, J. Exp. Med., 155, 1133, 1982 "GD3, A Prominent Ganglioside of Human Melanoma".
Nudelman, E., et al, J. Biol. Chem. 257, 12752, 1982 "Characterization of a Human Melanoma-Associated Ganglioside Antigen Defined by a Monoclonal Antibody, 4.2".
Yeh, M.T., et al, Int. J. Cancer, 29, 269,1982 "A Cell-Surface Antigen which is Present in the Ganglioside Fraction and Shared by Human Melanomas".
Morrison, S.L., et al, Proc, Natl. Acad. Sci. USA., 81, 6851, 1984 "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains".
Kameyama, K., et al, FEBS Letters, 244, 301, 1989 "Convenient Plasmid Vectors for Construction of Chimeric Mouse/Human Antibodies".
Gillies, S.D., et al, J. Immunol. Method, 125 191, 1989 "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes".
Reichmann, L., et al, Nature, 332, 323, 1988 "Reshaping Human Antibodies for Therapy".
Miyaji, H. et al, Cytotechnology, 3, 133, 1990 "Expression of Human Beta-Interferon in Namalwa KJM-1 which was Adapted to Serum-Free Medium".
Mizukami, T. et al, J. Biochem., 101, 1307, 1987 "A New SV40-Based Vector Developed for cDNA Expression in Animal Cells".
Kuwana, Y., et al, Biochem. Biopnys. Res. Commun., 149, 960, 1987 "Expression of Chimeric Receptor Composed of Immunoglobulin-Derived V Regions and T-Cell Receptor-Derived C Regions".
Kuwana, Y., et al, FEBS Letters, 219, 360, 1987 "Production of the Constant Domain of Murine T-Cell Receptor .rho.-Chain in Escherichia Coli".
Subramani, S., et al., Mol. Cell. Biol., 1, 854, 1981 "Expression of the Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simian Virus 40 Vectors".
Roeder, W., et al, Proc. Natl. Acad. Sci. USA., 78, 474, 1981 "Linkage of the Four .rho. Subclass Heavy Chain Genes".
Sakano, H., et al, Nature, 280, 288, 1979 "Sequences at the Somatic Recombinaton Sites of Immunoglobulin Light-Chain Genes".
Queen et al, PNAS 86:10029-1033 1989.
Sonnino et al, 437-464 1988 The Molecular Immunology of Complex Carbohydrates, Plenum Press New York.
Barker et al, Cancer Research 51(1):1440149 (1991) "Effect of a Chimeric Anti-Ganglioside GC2 Antibody on Cell-Mediated Lysis of Human Neuroblastoma Cells."f.
Ritter et al, Immunobiol. 182(1): 32-43 (1990) "Antibody Response to Immunization with Purified GD3 Ganglioside and GD3 Derivatives (Lactones, Amide and Gangliosidol) in the Mouse".
Waldmann Science 252:1657-1662 (1991).
Harris et al. TibTech 11:42-44 (1993).
Houghton et al. PNAS 82:1242-1246 (1985).
Wekmeister et al. Cancer Res. 47:225-230 (1987).
Hanai Nobuo
Hasegawa Mamoru
Kuwana Yoshihisa
Miyaji Hiromasa
Shitara Kenya
Eisenschenk Frank C.
Kyowa Hakko Kogyo Co. Ltd.
LandOfFree
Method of treating cancer using a chimera antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating cancer using a chimera antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cancer using a chimera antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-84715